Transcranial Photosensitizer-Free Laser Treatment of Glioblastoma in Rat Brain

Over sixty years, laser technologies have undergone a technological revolution and become one of the main tools in biomedicine, particularly in neuroscience, neurodegenerative diseases and brain tumors. Glioblastoma is the most lethal form of brain cancer, with very limited treatment options and a p...

Full description

Bibliographic Details
Main Authors: Oxana Semyachkina-Glushkovskaya, Sergey Sokolovski, Ivan Fedosov, Alexander Shirokov, Nikita Navolokin, Alla Bucharskaya, Inna Blokhina, Andrey Terskov, Alexander Dubrovski, Valeria Telnova, Anna Tzven, Maria Tzoy, Arina Evsukova, Daria Zhlatogosrkaya, Viktoria Adushkina, Alexander Dmitrenko, Maria Manzhaeva, Valeria Krupnova, Alessio Noghero, Denis Bragin, Olga Bragina, Ekaterina Borisova, Jürgen Kurths, Edik Rafailov
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/24/18/13696
Description
Summary:Over sixty years, laser technologies have undergone a technological revolution and become one of the main tools in biomedicine, particularly in neuroscience, neurodegenerative diseases and brain tumors. Glioblastoma is the most lethal form of brain cancer, with very limited treatment options and a poor prognosis. In this study on rats, we demonstrate that glioblastoma (GBM) growth can be suppressed by photosensitizer-free laser treatment (PS-free-LT) using a quantum-dot-based 1267 nm laser diode. This wavelength, highly absorbed by oxygen, is capable of turning triplet oxygen to singlet form. Applying 1267 nm laser irradiation for a 4 week course with a total dose of 12.7 kJ/cm<sup>2</sup> firmly suppresses GBM growth and increases survival rate from 34% to 64%, presumably via LT-activated apoptosis, inhibition of the proliferation of tumor cells, a reduction in intracranial pressure and stimulation of the lymphatic drainage and clearing functions. PS-free-LT is a promising breakthrough technology in non- or minimally invasive therapy for superficial GBMs in infants as well as in adult patients with high photosensitivity or an allergic reaction to PSs.
ISSN:1661-6596
1422-0067